Expres2ion Biotech

Financial Calendar

• 16/05/23

  Interim report, Q1 2023

• 24/05/23

  Annual General Meeting, 2023

• 17/08/23

  Half-year report, Q2 2023

• 16/11/23

  Interim report, Q3 2023

• 08/02/24

  Year-end report, 2023

Latest press releases

ExpreS2ion provides update on ABNCoV2 Phase III clinical trial

15-02-2023 Regulatory pressrelease

Hørsholm, Denmark, February 15, 2023– ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine. Today Bavarian Nordic announced that the top-line results are now anticipated around mid-2023 due to longer than expected recruitment…

Read more

ExpreS2ion will present fourth quarter and full-year 2022 results

13-02-2023 Non-regulatory pressrelease

Hørsholm, Denmark, February 13, 2023 – ExpreS2ion Biotech Holding AB (“ExpreS2ion") is pleased to announce that it will present fourth quarter and full-year 2022 results via webcast on February 15th, 2023, at 14:30 CET.

Read more

View all